Vertex Pharmaceuticals 株価情報 (NASDAQ: VRTX)

最新ニュース Vertex Pharmaceuticals (NASDAQ:VRTX) 株価情報

Vertex Pharmaceuticals

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Analyst Ratings

VRTX

Vertex Pharmaceuticals（NASDAQ:VRTX）に14人のアナリストが過去3か月間で分析を行ったところ、その視点は強気から弱気まで多様なものとなった。

14人のアナリスト分析からVertexの市場動向を追う

Vertex Pharmaceuticals Incorporated - Common Stock

Vertex Pharmaceuticals Inc

In a court filing on Monday, the Department of Health and Human Services (HHS) challenged Vertex Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>), defending its stance that the company&#8217;s proposed fertility services program would breach anti-kickback laws. The program is tied to Vertex&#8217;s gene-editing therapy Casgevy for sickle cell disease and transfusion-dependent beta-thalassemia.
Vertex&nbsp;<a href="https://assets.bwbx.io/documents/users/iqjWHBFdfxIU/rnMCje2Jspgw/v0" target="_blank" rel="noreferrer noopener">sued</a>&nbsp;the HHS in July 2024.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42324351/fda-approved-sickle-cell-therapies-from-bluebird-bio-and-vertex-join-medicaid-innovation-program" rel="noreferrer noopener">FDA-Approved Sickle Cell Therapies From Bluebird Bio And Vertex Join Medicaid Innovation Program</a>
The gene-editing treatment requires high-dose chemotherapy to clear stem cells from the bone marrow, often causing severe side effects, including infertility. To support patients, Vertex provides financial assistance for fertility preservation options like freezing eggs, embryos or reproductive tissues.
Last year, the HHS Office of Inspector General (OIG) confirmed its decision that it could not issue a favorable advisory opinion. According to OIG, the program implicates the anti-kickback statute, poses more than a low risk of fraud and abuse, and does not promote access to gene therapy care.
Also Read: <a href="https://www.benzinga.com/25/01/42987342/vertex-pharmaceuticals-sets-sights-on-expanding-portfolio-with-alyftrek-approval-pain-treatment-progress-and-diabetes-trials" target="_blank" rel="noreferrer noopener">Vertex Pharmaceuticals Sets Sight on Expanding Portfolio with Alyftrek Approval, Pain Treatment Progress, and Diabetes Trials</a>
The biotech challenged this allegation, "the Fertility Preservation Program would not improperly skew medical decision-making or provide an improper inducement to prescribe," nor would it persuade patients to "undergo treatment with Casgevy in exchange for the Fertility Preservation Program."
Endpoints <a target="_blank" href="https://endpts.com/wp-content/uploads/2025/01/show_temp.pdf" rel="noreferrer noopener">published</a> a copy of the lawsuit online Wednesday.
HHS laid out several arguments, claiming Vertex's attempts to &#8220;twist the statute's meaning&#8221; and that the biotech is "grasping at straws&#8230;"
"The point is that Vertex's offer of fertility treatment in exchange for purchasing its product, and only its product, is meant to induce patients to choose that product when they otherwise might not. That is a quintessential quid pro quo," the HHS said.
"Vertex is not offering $70,000 to any sickle cell patient who undergoes myeloablative conditioning to prepare for treatment, regardless whether that patient elects to purchase Vertex's product, or its competitor's similar gene-therapy product, or a bone- and blood-marrow transplant," the HHS wrote. "Vertex is only offering payments on behalf of patients who select its own product."
&#8220;Vertex then posits that its $70,000 offer will not interfere with or skew clinical decisionmaking because fertility services "benefit a patient's quality of life," HHS noted.
&#8220;This is nonsensical. Many offers of remuneration would enhance patient quality of life, but that doesn't render them lawful," the HHS added.
VRTX Price Action: Vertex stock is down 1.41% at $418.29 at publication Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/43036259/canadian-national-railways-valuation-is-an-opportunity-analyst-shifts-to-bullish-outlook" target="_blank" rel="noreferrer noopener">Canadian National Railway&#8217;s Valuation Is An Opportunity, Analyst Shifts To Bullish Outlook</a></li>
</ul>
Photo: Courtesy Vertex Pharmaceuticals

Biotech

Government

Large Cap

News

Health Care

Legal

General

HHS Challenges Vertex Over Fertility Services Program Tied To Casgevy Gene Therapy, Says Company Is 'Grasping at Straws'

Vertex Pharmaceuticals's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NYSE">VRTX</a>) short percent of float has risen 12.41% since its last report. The company recently reported that it has 3.96 million shares sold short, which is 1.54% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.6 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Vertex Pharmaceuticals Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736956825_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Vertex Pharmaceuticals has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Vertex Pharmaceuticals's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Vertex Pharmaceuticals's peer group average for short interest as a percentage of float is 5.33%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

How Is The Market Feeling About Vertex Pharmaceuticals?

Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) has outperformed the market over the past 10 years by 1.52% on an annualized basis producing an average annual return of 12.68%. Currently, Vertex Pharmaceuticals has a market capitalization of $106.01 billion. 
Buying $100 In VRTX: If an investor had bought $100 of VRTX stock 10 years ago, it would be worth $330.01 today based on a price of $411.66 for VRTX at the time of writing.
<h3>Vertex Pharmaceuticals's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736889310_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth Today

On Sunday, Vertex Pharmaceuticals Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) announced multiple program updates, including:
<ul>
<li>In December, the FDA approved Vertex's Alyftrek (vanzacaftor / tezacaftor / deutivacaftor), a once-daily triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator for cystic fibrosis (CF) in people 6 years and older who have at least one F508del mutation or another mutation in the CFTR gene that is <a href="https://www.benzinga.com/pressreleases/24/12/b42628470/vertex-announces-us-fda-approval-of-alyftrek-a-once-daily-next-in-class-cftr-modulator-for-the-tre" target="_blank" rel="noreferrer noopener">responsive to ALYFTREK</a>. Vertex raised its CF patient estimates across major markets to 94,000, while reimbursement arrangements are expected to broaden treatment access for <a href="https://www.benzinga.com/pressreleases/25/01/b42935907/vertex-provides-pipeline-and-business-updates-in-advance-of-upcoming-investor-meetings" target="_blank" rel="noreferrer noopener">10,000 eligible individuals</a>.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42652152/vertex-pharmaceuticals-alyftrek-is-an-accretive-opportunity-on-top-and-bottom-lines-say-bullish-analyst" rel="noreferrer noopener">Vertex Pharmaceuticals: Alyftrek Is An ‘Accretive Opportunity' On Top- And Bottom-Lines, Says Bullish Analyst</a>
<ul>
<li>In December, Vertex's CASGEVY gained regulatory approval in the UAE for sickle cell disease and transfusion-dependent beta-thalassemia.</li>
<li>Suzetrigine for moderate-to-severe acute pain awaits an FDA decision by January 30, 2025, under Priority Review. This non-opioid candidate aligns with the newly effective NOPAIN Act, potentially improving pain management alternatives <a href="https://www.benzinga.com/24/12/42599745/why-is-vertex-pharmaceuticals-stock-trading-on-thursday-lower-after-back-pain-trial-data" target="_blank" rel="noreferrer noopener">and ensuring Medicare support</a>.</li>
<li>In type 1 diabetes, zimislecel entered Phase 3 trials targeting 125,000 patients. Complementary therapies, including encapsulated islet cells in VX-264, are advancing, with pivotal data expected in 2025.</li>
</ul>
RBC Capital Markets says Vertex management is optimistic about the recently approved Alyftrek. They predict that most of the 6,000 patients who stopped using other CFTR modulators and many currently on existing treatments will switch to this next-gen therapy.
RBC analyst Brian Abrahams writes that in acute pain, Suzetrigine pricing may be higher than anticipated, as the company emphasized that it doesn't want to risk the long-term value of its pain portfolio or the success in chronic pain just for quick approval of its first drug. The analyst also noted that formulary placement and payer discussions will affect the initial launch.
RBC Capital maintains a Neutral rating on Vertex.
Goldman Sachs analyst Salveen Richter writes suzetrigine could become the first non-opioid treatment for acute pain approved in over 20 years.
It can generate billions in revenue from both acute and possibly chronic pain. If approved, it would give Vertex Pharmaceuticals a significant new revenue source beyond cystic fibrosis, especially as income from Casgevy remains low in the near term, helping to diversify <a target="_blank" href="https://www.benzinga.com/general/biotech/24/12/42396975/vertex-has-5-billion-plus-opportunity-in-pain-and-kidney-disease-programs-analyst-upgrades-stock" rel="noreferrer noopener">its commercial portfolio</a>.
Price Action: VRTX stock is down 0.46% at $411.47 at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/01/42982029/emcor-expands-southeast-footprint-with-865-million-miller-electric-deal" target="_blank" rel="noreferrer noopener">EMCOR Expands Southeast Footprint With $865 Million Miller Electric Deal</a></li>
</ul>
Image via Vertex Pharmaceuticals

Analyst Color

Vertex Pharmaceuticals Sets Sight on Expanding Portfolio with Alyftrek Approval, Pain Treatment Progress, and Diabetes Trials

"2024 marked another year of excellent progress for Vertex, as we reached more people with CF than ever before, began a new era of commercial diversification, and advanced and broadened our clinical stage pipeline," said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. "In 2025, we are poised to diversify our business further across multiple dimensions: our revenue, as we continue the launches of CASGEVY, ALYFTREK and potentially launch suzetrigine in acute pain; our pipeline, as we progress four potentially transformative medicines through pivotal trials; and our geographic footprint, as we expand both our commercial and clinical presence globally."

Reported Earlier, Vertex Unveils Comprehensive Updates On CF, SCD, And Pipeline Progress Across Multiple Disease Areas For 2025

Ratings for Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) were provided by 23 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">9</td>
<td align="right">6</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $503.35, a high estimate of $600.00, and a low estimate of $408.00. A 1.43% drop is evident in the current average compared to the previous average price target of $510.67. 
<img src="https://www.benzinga.com/files/images/story/2025/1736532045_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The perception of Vertex Pharmaceuticals by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$460.00</td>
<td>$555.00</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$460.00</td>
<td>$550.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$430.00</td>
<td>$426.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$500.00</td>
<td>$503.00</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$418.00</td>
<td>$509.00</td>
</tr>
<tr>
<td>Evan Seigerman</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$520.00</td>
<td>$566.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$535.00</td>
<td>$600.00</td>
</tr>
<tr>
<td>Ying Huang</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$522.00</td>
<td>$545.00</td>
</tr>
<tr>
<td>Paul Matteis</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$494.00</td>
<td>$490.00</td>
</tr>
<tr>
<td>Michael Yee</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$550.00</td>
<td>$500.00</td>
</tr>
<tr>
<td>Geoff Meacham</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Buy</td>
<td>$575.00</td>
<td>-</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Sell</td>
<td>$408.00</td>
<td>$361.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$486.00</td>
<td>$480.00</td>
</tr>
<tr>
<td>Colin Bristow</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$586.00</td>
<td>$562.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$480.00</td>
<td>$480.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$451.00</td>
<td>$437.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$503.00</td>
<td>$510.00</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$476.00</td>
<td>$473.00</td>
</tr>
<tr>
<td>Hartaj Singh</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$540.00</td>
<td>$550.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$600.00</td>
<td>$600.00</td>
</tr>
<tr>
<td>Colin Bristow</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$562.00</td>
<td>$477.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Perform</td>
<td>$480.00</td>
<td>-</td>
</tr>
<tr>
<td>Ying Huang</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$541.00</td>
<td>$550.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Vertex Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Vertex Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Vertex Pharmaceuticals's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
To gain a panoramic view of Vertex Pharmaceuticals's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/VRTX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Vertex Pharmaceuticals analyst ratings.</a>
<h2>Get to Know Vertex Pharmaceuticals Better</h2>
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
<h3>Breaking Down Vertex Pharmaceuticals's Financial Performance</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Vertex Pharmaceuticals's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 11.61%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Vertex Pharmaceuticals's net margin is impressive, surpassing industry averages. With a net margin of 37.71%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Vertex Pharmaceuticals's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 6.88% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Vertex Pharmaceuticals's ROA excels beyond industry benchmarks, reaching 4.93%. This signifies efficient management of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.11, Vertex Pharmaceuticals adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: Simplified</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 23 Analyst Projections For Vertex Pharmaceuticals

Wells Fargo analyst Mohit Bansal maintains Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Overweight and lowers the price target from $555 to $460.

Price Target

Wells Fargo Maintains Overweight on Vertex Pharmaceuticals, Lowers Price Target to $460

Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) shares are just "too low to sell," according to Jim Cramer, host of CNBC&#8217;s "<a href="https://www.benzinga.com/topic/mad-money-lightning-round">Mad Money Lightning Round</a>." 
Hold the stock and let "the dividend do the job," Cramer advises, preferring to wait for "some good news" <a href="https://www.benzinga.com/general/biotech/23/03/31319372/seagens-43b-deal-to-double-pfizers-early-stage-oncology-pipeline-seagen-says-is-right-step">on the Seagen acquisition</a>.
Pfizer stock is down more than 7% over the past year. With the Covid wave having past, the pharma giant is in talks to extend its collaboration with medical AI start-up firm PostEra to design antibody-drug conjugates.
Turning to Vertex Pharmaceuticals Inc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) new wonder drug suzetrigine, which received FDA approval last year, Cramer said it was disappointing that the drug does not seem to be working. "I was praying they would have something that wouldn&#8217;t be addictive," he added.
Although the pharma company has several "great drugs," there seems to be a limited upside to the stock because suzetrigine was supposed to be the "drug of the future for Vertex," Cramer added.
When asked about Serve Robotics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERV#NASDAQ">SERV</a>), Cramer suggested Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) for exposure to the sector. Calling Nvidia the "king of robots," he further said, "There's nobody else."
Cramer said he would be a seller of QuantumScape Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QS#NYSE">QS</a>). Referring to the steep decline in Powell Industries Inc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POWL#NASDAQ">POWL</a>) shares, Cramer said, "I did not see that coming." The decline has been a "big, big disappointment," he added.
Price Action
<ul>
<li>Pfizer's stock declined by 1% to close at $26.86 on Wednesday.</li>
<li>Shares of Vertex Pharmaceuticals Inc settled higher by 0.93% at $412.11.</li>
<li>Serve Robotics tanked almost 10% on Wednesday.</li>
<li>Nvidia's share price ended the trading session almost flat.</li>
<li>QuantumScape's stock plunged 9% to close at $5.72.</li>
<li>Shares of Powell Industries fell 3.26% to $229.38.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42900074/how-to-earn-500-a-month-from-synovus-financial-stock-ahead-of-q4-earnings">How To Earn $500 A Month From Synovus Financial Stock Ahead Of Q4 Earnin</a>gs</li>
</ul>
Image: Shutterstock

Markets

Media

NVDA

POWL

SERV

Pfizer Is 'Too Low To Sell,' Jim Cramer Says: Recommends Nvidia For Robotics Exposure

Vertex And Zai Lab Announce Strategic Agreement To Develop And Commercialize Povetacicept In Mainland China, Hong Kong Sar, Macau Sar, Taiwan Region And Singapore

Vertex Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) is grappling with bearish technical signals as its stock forms a <a href="https://www.benzinga.com/topic/death-cross">dreaded Death Cross</a>.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010725&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="628" height="483" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/07110320/Screenshot-2025-01-07-at-7.25.52-PM.png" alt="" class="wp-image-722205" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/07110320/Screenshot-2025-01-07-at-7.25.52-PM.png 628w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/07110320/Screenshot-2025-01-07-at-7.25.52-PM-300x231.png 300w" sizes="(max-width: 628px) 100vw, 628px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010725&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
This occurs when the 50-day moving average falls below the 200-day moving average, often seen as a harbinger of prolonged bearish momentum. For Vertex, the technical woes align with a broader decline—down 15% over six months and nearly 14% in the past month alone.
Read Also: <a href="https://www.benzinga.com/insights/news/25/01/42851189/if-you-invested-1000-in-this-stock-20-years-ago-you-would-have-this-much-today">If You Invested $1000 In This Stock 20 Years Ago, You Would Have This Much Today</a>
<h2 class="wp-block-heading">Cystic Fibrosis Successes Overshadowed By Painkiller Setback</h2>
Despite commanding over 90% of its revenue from its cystic fibrosis drug franchise, Vertex has been unable to fend off investor skepticism. 
In 2024, the company made waves with CASGEVY, the first gene-editing-based treatment for Sickle Cell Disease. However, enthusiasm waned in December after its much-anticipated non-addictive painkiller failed to meet clinical trial goals, leading to an 11% slide in shares, <a href="https://www.insidermonkey.com/blog/jim-cramers-take-on-vertex-pharmaceuticals-vrtx-bold-predictions-for-the-future-1417241/">according </a>to Insider Monkey.
<h2 class="wp-block-heading">VRTX Stock Charts Are Not Encouraging</h2>
VRTX stock is flashing multiple sell signals:
<ul>
<li>Moving Averages: VRTX stock, at $402.49, is below all key averages, including the 50-day ($456.92) and 200-day ($457.35), reinforcing the Death Cross.</li>
<li>MACD: A negative reading of -17.17 signals strong bearish momentum.</li>
<li>RSI: At 32.59, the stock is approaching oversold levels but hasn't yet hit the reversal zone.</li>
</ul>
<h2 class="wp-block-heading">Cramer's Call Under Pressure</h2>
Back in August, Jim Cramer lauded Vertex as a promising player in biotech, emphasizing its groundbreaking work in cystic fibrosis <a href="https://www.benzinga.com/24/08/40624639/jim-cramer-hold-on-to-builders-firstsource-heres-the-problem-with-viking-therapeutics">and pain management.</a>
Since then, the stock has dropped nearly 18%, reflecting the volatility that often plagues the biotech sector.
Vertex's technical and fundamental challenges suggest that investors may need patience to see a rebound.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42652152/vertex-pharmaceuticals-alyftrek-is-an-accretive-opportunity-on-top-and-bottom-lines-say-bullish-analyst">Vertex Pharmaceuticals: Alyftrek Is An &#8216;Accretive Opportunity&#8217; On Top- And Bottom-Lines, Says Bullish Analyst</a></li>
</ul>
Photo: Shutterstock

Technicals

Vertex Grapples With Bearish Chart As Death Cross Emerges

Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) has outperformed the market over the past 20 years by 11.7% on an annualized basis producing an average annual return of 20.1%. Currently, Vertex Pharmaceuticals has a market capitalization of $105.56 billion. 
Buying $1000 In VRTX: If an investor had bought $1000 of VRTX stock 20 years ago, it would be worth $39,441.77 today based on a price of $409.89 for VRTX at the time of writing.
<h3>Vertex Pharmaceuticals's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736264708_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 20 Years Ago, You Would Have This Much Today

Vertex will utilize Orna's novel and proprietary LNP delivery solutions to enhance efforts in developing next generation gene editing therapies for patients with Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT).
Under the terms of the agreement, Orna will receive upfront payments of $65 million, including an investment in the form of a convertible note, and is eligible to receive up to $635 million based upon the achievement of specified pre-clinical, research, development, regulatory and commercial milestones related to SCD/TDT products.
Additionally, Orna is further eligible to receive up to $365 million in additional option fees and milestones per product for up to ten additional products if Vertex options rights in additional indications.&nbsp;

Contracts

Orna Therapeutics Enters Three-year Strategic Research Collaboration With Vertex Pharmaceuticals;  Orna To Receive $65M Upfront Payment And Is Eligible To Receive Up To $635M Milestones

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/27/24</td>
<td>$26.50</td>
<td>$152.0K</td>
<td>24.2K</td>
<td>8.7K</td>
</tr>
<tr>
<td>TLRY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$1.50</td>
<td>$34.6K</td>
<td>54.8K</td>
<td>5.9K</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$30.00</td>
<td>$195.0K</td>
<td>6.7K</td>
<td>1.8K</td>
</tr>
<tr>
<td>IOVA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$7.50</td>
<td>$41.6K</td>
<td>7.8K</td>
<td>1.7K</td>
</tr>
<tr>
<td>AVXL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$17.00</td>
<td>$57.1K</td>
<td>1.5K</td>
<td>1.4K</td>
</tr>
<tr>
<td>LQDA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$10.00</td>
<td>$34.0K</td>
<td>1.8K</td>
<td>93</td>
</tr>
<tr>
<td>VRTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$410.00</td>
<td>$28.2K</td>
<td>701</td>
<td>63</td>
</tr>
<tr>
<td>TMDX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$75.00</td>
<td>$33.4K</td>
<td>94</td>
<td>41</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$275.00</td>
<td>$30.0K</td>
<td>29</td>
<td>24</td>
</tr>
<tr>
<td>CI</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$280.00</td>
<td>$26.1K</td>
<td>848</td>
<td>8</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we notice a call option trade that happens to be bearish, expiring in 1 day(s) on December 27, 2024. This event was a transfer of 8000 contract(s) at a $26.50 strike. The total cost received by the writing party (or parties) was $152.0K, with a price of $19.0 per contract. There were 24292 open contracts at this strike prior to today, and today 8717 contract(s) were bought and sold. 
• Regarding TLRY (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>), we observe a call option sweep with bullish sentiment. It expires in 22 day(s) on January 17, 2025. Parties traded 1500 contract(s) at a $1.50 strike. This particular call needed to be split into 30 different trades to become filled. The total cost received by the writing party (or parties) was $34.6K, with a price of $23.0 per contract. There were 54857 open contracts at this strike prior to today, and today 5953 contract(s) were bought and sold. 
• For HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we notice a call option trade that happens to be bearish, expiring in 22 day(s) on January 17, 2025. This event was a transfer of 1000 contract(s) at a $30.00 strike. The total cost received by the writing party (or parties) was $195.0K, with a price of $195.0 per contract. There were 6719 open contracts at this strike prior to today, and today 1888 contract(s) were bought and sold. 
• For IOVA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOVA#NASDAQ">IOVA</a>), we notice a call option trade that happens to be bearish, expiring in 22 day(s) on January 17, 2025. This event was a transfer of 757 contract(s) at a $7.50 strike. The total cost received by the writing party (or parties) was $41.6K, with a price of $55.0 per contract. There were 7847 open contracts at this strike prior to today, and today 1775 contract(s) were bought and sold. 
• Regarding AVXL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>), we observe a call option sweep with bearish sentiment. It expires in 204 day(s) on July 18, 2025. Parties traded 200 contract(s) at a $17.00 strike. This particular call needed to be split into 8 different trades to become filled. The total cost received by the writing party (or parties) was $57.1K, with a price of $285.0 per contract. There were 1543 open contracts at this strike prior to today, and today 1410 contract(s) were bought and sold. 
• Regarding LQDA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LQDA#NASDAQ">LQDA</a>), we observe a call option sweep with bearish sentiment. It expires in 386 day(s) on January 16, 2026. Parties traded 83 contract(s) at a $10.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $34.0K, with a price of $410.0 per contract. There were 1892 open contracts at this strike prior to today, and today 93 contract(s) were bought and sold. 
• Regarding VRTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>), we observe a call option sweep with bullish sentiment. It expires in 22 day(s) on January 17, 2025. Parties traded 25 contract(s) at a $410.00 strike. This particular call needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $28.2K, with a price of $1130.0 per contract. There were 701 open contracts at this strike prior to today, and today 63 contract(s) were bought and sold. 
• For TMDX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>), we notice a put option sweep that happens to be bullish, expiring in 112 day(s) on April 17, 2025. This event was a transfer of 18 contract(s) at a $75.00 strike. This particular put needed to be split into 11 different trades to become filled. The total cost received by the writing party (or parties) was $33.4K, with a price of $1860.0 per contract. There were 94 open contracts at this strike prior to today, and today 41 contract(s) were bought and sold. 
• Regarding AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we observe a call option sweep with bullish sentiment. It expires in 141 day(s) on May 16, 2025. Parties traded 23 contract(s) at a $275.00 strike. This particular call needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $30.0K, with a price of $1305.0 per contract. There were 29 open contracts at this strike prior to today, and today 24 contract(s) were bought and sold. 
• For CI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), we notice a put option trade that happens to be bullish, expiring in 386 day(s) on January 16, 2026. This event was a transfer of 8 contract(s) at a $280.00 strike. The total cost received by the writing party (or parties) was $26.1K, with a price of $3266.0 per contract. There were 848 open contracts at this strike prior to today, and today 8 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

AMGN

AVXL

Hims & Hers Health, Inc. Class A Common Stock

HIMS

IOVA

LQDA

TLRY

TMDX

10 Health Care Stocks With Whale Alerts In Today's Session

Vertex Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) last week announced that the Phase 2 study of suzetrigine for painful lumbosacral radiculopathy (LSR) had <a href="https://www.benzinga.com/24/12/42599745/why-is-vertex-pharmaceuticals-stock-trading-on-thursday-lower-after-back-pain-trial-data">met its primary endpoint</a>.
The company announced that the FDA had approved Alyftrek (or vanzacaftor triple) in cystic fibroris (CF) six years and older, in-line with expectations, according to Goldman Sachs.
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/587781dc5064ed0001730067/salveen-richter">Analyst Salveen Richter</a> maintained a Buy rating for Vertex Pharmaceuticals and price target of $602.
The Vertex Pharmaceuticals Thesis: During the initial launch of Alyftrek, the company is likely to target those patients who had previously started on one of its CFTR modulators but have discontinued over time, Richter said in the note.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
Alyftrek expands the company's CF franchise to address around 6,000 such patients, he added.
Vertex Pharmaceuticals could also target patients who are currently on one of its other CF therapies, the analyst stated.
"Importantly, in addition to serving as a top-line growth opportunity, vanzacaftor enables higher margins and is dosed once daily, which provides incentive for switching notably in younger age groups," Richter wrote. This means Alyftrek provides the company with an "accretive opportunity" on both the top- and bottom-lines, he further said.
VRTX Price Action: Shares of Vertex Pharmaceuticals had declined by 0.38% to $395.75 at the time of publication on Monday late morning.
Read More: <a href="https://www.benzinga.com/news/large-cap/24/12/42638379/novo-nordisk-super-micro-computer-and-arm-are-among-top-large-cap-losers-last-week-december-16-20-are-the-others-in-your-portfolio">Novo Nordisk, Super Micro Computer And Arm Are Among Top Large Cap Losers Last Week (December 16-20): Are The Others In Your Portfolio?</a>

Long Ideas

Reiteration

Vertex Pharmaceuticals: Alyftrek Is An 'Accretive Opportunity' On Top- And Bottom-Lines, Says Bullish Analyst

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Loop Capital increased Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) price target from $500 to $550. Loop Capital analyst Eric Beder maintained a Buy rating. Microsoft shares closed at $436.60 on Friday. See how other analysts view this stock.</li>
<li>Truist Securities cut the price target for Vertex Pharmaceuticals Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) from $550 to $460. Truist Securities analyst Joon Lee maintained a Buy rating. Vertex Pharmaceuticals shares closed at $397.27 on Friday. See how other analysts view this stock.</li>
<li>Goldman Sachs lowered the price target for Lennar Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEN#NYSE">LEN</a>) from $190 to $162. Goldman Sachs analyst Susan Maklari maintained a Neutral rating. Lennar shares closed at $138.08 on Friday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Benchmark boosted the price target for Humacyte, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUMA#NASDAQ">HUMA</a>) from $15 to $17. Benchmark analyst Bruce Jackson maintained a Buy rating. Humacyte shares closed at $4.64 on Friday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Loop Capital Snowflake Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) price target from $185 to $205. Loop Capital analyst Mark Schappel maintained a Buy rating. Snowflake shares settled at $166.29 on Friday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>RBC Capital raised Uniti Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UNIT#NASDAQ">UNIT</a>) price target from $5.5 to $6. RBC Capital analyst Bora Lee maintained a Sector Perform rating. Uniti shares closed at $5.70 on Friday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Loop Capital increased Datadog, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDOG#NASDAQ">DDOG</a>) price target from $160 to $200. Loop Capital analyst Yun Kim maintained a Buy rating. Datadog shares closed at $149.46 on Friday.  <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stifel cut the price target for Schlumberger Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>) from $60 to $59. Stifel analyst Stephen Gengaro maintained a Buy rating. Schlumberger shares settled at $36.83 on Friday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays raised Carnival Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCL#NYSE">CCL</a>) price target from $31 to $32. Barclays analyst Brandt Montour maintained an Overweight rating. Carnival shares closed at $26.80 on Friday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. increased SoundHound AI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>) price target from $8 to $26. HC Wainwright &amp; Co. analyst Scott Buck maintained a Buy rating. SoundHound AI shares closed at $21.75 on Friday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42616196/jim-cramer-likes-walmart-recommends-buying-this-very-very-good-financial-stock">Jim Cramer Likes Walmart, Recommends Buying This &#8216;Very, Very Good&#8217; Financial Stock</a></li>
</ul>

DDOG

HUMA

MSFT

SNOW

SOUN

UNIT

Microsoft To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Monday

Truist Securities analyst Joon Lee maintains Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Buy and lowers the price target from $550 to $460.

Truist Securities Maintains Buy on Vertex Pharmaceuticals, Lowers Price Target to $460

Scotiabank analyst Greg Harrison maintains Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Sector Perform and raises the price target from $426 to $430.

Scotiabank Maintains Sector Perform on Vertex Pharmaceuticals, Raises Price Target to $430

JP Morgan analyst Jessica Fye maintains Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Overweight and lowers the price target from $503 to $500.

JP Morgan Maintains Overweight on Vertex Pharmaceuticals, Lowers Price Target to $500

These eleven large-cap stocks were the worst performers in the last week. Are they in your portfolio?
<ol>
<li>Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) shares dipped 20.52% after the company released headline results from the REDEFINE 1 Phase 3 <a href="https://www.benzinga.com//node/42613036" target="_blank" rel="noreferrer noopener">trial in the global REDEFINE program</a>.</li>
<li>Vertex Pharmaceuticals Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) stock declined 14.33% after the company announced results from its <a href="https://www.benzinga.com//node/42599745" target="_blank" rel="noreferrer noopener">Phase 2 study of Suzetrigine</a>.</li>
<li>XPO, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPO#NYSE">XPO</a>) shares were down 13.47%.</li>
<li>Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) shares fell 13.33% last week as the company is <a href="https://www.benzinga.com//node/42520765" target="_blank" rel="noreferrer noopener">set to be removed</a> from the Nasdaq 100 Index.</li>
<li>Nu Holdings Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NU#NYSE">NU</a>) stock plummeted 13.07%. A new government fiscal spending package and last week&#8217;s central bank rate hike could erode global investor confidence and raise concerns over the nation&#8217;s deficit.</li>
<li>Arm Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) stock was down 13.01%, likely due to continued weakness stemming from its <a href="https://www.benzinga.com//node/42538739" target="_blank" rel="noreferrer noopener">ongoing legal dispute</a> with Qualcomm Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>).</li>
<li>Micron Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) shares decreased 12.08% after the company reported mixed earnings results and issued weak guidance for the current quarter. <a href="https://www.benzinga.com//node/42594359" target="_blank" rel="noreferrer noopener">Multiple analysts also lowered price forecasts</a>.</li>
<li>Paycom Software, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAYC#NYSE">PAYC</a>) stock lost 11.63% last week, a result of the Fed rate decision that caused a selloff in software stocks.</li>
<li>Cintas Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTAS#NASDAQ">CTAS</a>) stock declined 11.50% after the company reported <a href="https://www.benzinga.com//node/42588404" target="_blank" rel="noreferrer noopener">second-quarter financial results</a>. Several analysts lowered <a href="https://www.benzinga.com/quote/ctas/analyst-ratings" target="_blank" rel="noreferrer noopener">the price forecast on the stock</a>.</li>
<li>Warner Bros. Discovery, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>) <a href="https://www.benzinga.com//node/42603589" target="_blank" rel="noreferrer noopener">declined 11.43%</a>.</li>
<li>monday.com Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDY#NASDAQ">MNDY</a>) stock dived 11.20% after Citigroup cut its price forecast <a href="https://www.benzinga.com/quote/mndy/analyst-ratings" target="_blank" rel="noreferrer noopener">on the stock from $338 to $302</a>.</li>
</ol>
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/12/42638256/teva-pharmaceutical-li-auto-and-darden-restaurants-are-among-top-large-cap-gainers-last-week-december-16-20-are-the-others-in-your-portfolio" target="_blank" rel="noreferrer noopener">Teva Pharmaceutical, Li Auto, And Darden Restaurants Are Among Top Large Cap Gainers Last Week (December 16-20): Are The Others In Your Portfolio?</a></li>
</ul>
Photo via Shutterstock

Movers

CTAS

CVNA

MNDY

MSTR

PAYC

QCOM

SMCI

Novo Nordisk, Super Micro Computer And Arm Are Among Top Large Cap Losers Last Week (December 16-20): Are The Others In Your Portfolio?

On December 20, 2024, the U.S. Food and Drug Administration approved ALYFTREK&#x2122; (vanzacaftor/tezacaftor/deutivacaftor) for the treatment of cystic fibrosis in people 6 years and older who have at least one F508del mutation or another mutation in the cystic fibrosis transmembrane conductance regulator gene that is responsive to ALYFTREK.
 &nbsp;
We have established a wholesale acquisition cost for ALYFTREK in the United States of $370,269 on an annual basis ($28,404 per 28-day pack).

Vertex Pharmaceuticals Establishes Wholesale Acquisition Cost For Alyftrek In U.S. Of $370,269 On Annual Basis ($28,404 Per 28-day Pack)

Morgan Stanley analyst Terence Flynn maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of $4...

Vertex Pharmaceuticals: Balancing Growth Prospects and Uncertainties with a Hold Rating

In a report released today, William Pickering from Bernstein maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), with a pr...

Bernstein Sticks to Its Hold Rating for Vertex Pharmaceuticals (VRTX)

In a report released today, Gena Wang from Barclays maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), with a price targe...

Barclays Reaffirms Their Hold Rating on Vertex Pharmaceuticals (VRTX)

Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), retaining the price target of $52...

Vertex Pharmaceuticals: Strategic Advancements and Promising Pipeline Drive Buy Rating

McKesson, Vertex Pharmaceuticals among top healthcare Quant picks before Q4 earnings

CRISPR Therapeutics: Unfairly Punished By The Issues Of Its Peers

Next Century Growth Investors Q4 2024 Commentary

In a report released today, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report)...

Bank of America Securities Reaffirms Their Buy Rating on Vertex Pharmaceuticals (VRTX)

The biotechnology market experiences significant growth, fueled by advancements in genetic therapies and supportive global regulations. Considering the advancements, fundamentally solid biotech stocks Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), and Regeneron Pharmaceuticals (REGN) are emerging as top choices for investors seeking transformative opportunities. Read further… The U.S. biotech sector is experiencing significant growth, fueled by groundbreaking advancements in genetic therapies, personalized medicine, and immunotherapy. As the industry continues to push the boundaries of medical innovation, companies driving breakthroughs in gene therapy and genetic treatments are gaining attention.
Therefore, solid biotech stocks Gilead Sciences, Inc. (<a href="https://stocknews.com/stock/GILD/">GILD</a>), Vertex Pharmaceuticals Incorporated (<a href="https://stocknews.com/stock/VRTX/">VRTX</a>), and Regeneron Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/REGN/">REGN</a>) coulc be ideal buys.
U.S. biotech stocks are primarily driven by advancements in medical research, regulatory approvals, and the ongoing demand for innovative treatments. Breakthroughs in gene therapy, personalized medicine, and immunotherapy are central to investor optimism, as these areas offer potential to address previously untreatable diseases.
Gene therapies are rapidly transforming the landscape of healthcare, offering the potential to cure or significantly improve the treatment of a wide array of diseases. By directly addressing the root causes of genetic disorders through the modification or replacement of defective genes, these therapies provide long-term or even permanent solutions for conditions that were once considered untreatable. The global biotechnology market, which was valued at <a href="https://www.precedenceresearch.com/biotechnology-market">$1.55 trillion in 2024</a>, is projected to reach $4.61 trillion by 2034, at a CAGR of 11.5%.
Considering this growing trajectory, let's discuss further about the <a href="https://stocknews.com/category/biotech/">Biotech</a> stocks:
Stock #3: Vertex Pharmaceuticals Incorporated (<a href="https://stocknews.com/stock/VRTX/">VRTX</a>)
VRTX is a leading biotech company that focuses on treatments for cystic fibrosis and other conditions, including sickle cell disease, diabetes, and cancer, with key products like TRIKAFTA and a diverse clinical pipeline.
In the fiscal third quarter that ended September 30, 2024, VRTX's net product revenues increased 11.6% year-over-year to $ 2.77 billion. Its non-GAAP operating income grew 11.4% from the year-ago value to $1.31 billion. In addition, the non-GAAP net income came in at $ 1.14 billion and $4.38 per share, up 7.5% and 7.4% over the prior-year quarter, respectively.
Street expects VRTX's <a href="https://www.investopedia.com/terms/r/revenue.asp">revenue</a> for the fiscal fourth quarter (ending December 31, 2024) to increase 10.6% year-over-year to $ 2.79 billion. Its EPS for the same quarter is expected to be $4.06. In addition, it surpassed the consensus revenue and EPS estimates in three of the trailing four quarters, which is promising.
The stock plunged down to 4% in the past year to close the last trading session at $402.49.
VRTX's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect its robust outlook. The stock has an overall rating of B, equating to a Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 distinct factors, with each factor weighted to an optimal degree.
VRTX has a B grade in Value. It is ranked #33 out of 336 stocks in the <a href="https://stocknews.com/category/biotech/">Biotech industry</a>.
Beyond what we have stated above, we also have given VRTX grades for Growth, Momentum, Stability, Sentiment, and Quality. Get all the VRTX's ratings <a href="https://stocknews.com/stock/VRTX/">here</a>.
Stock #2: Regeneron Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/REGN/">REGN</a>)
REGN develops and commercializes medicines for various diseases, including eye disorders, asthma, cancer, and rare conditions. Key products include EYLEA, Dupixent, and Libtayo, alongside advanced research in gene editing and T cell therapies through collaborations.
On December 19, REGN announced positive Phase 2 results for its monoclonal antibodies REGN7508 and REGN9933, targeting distinct domains of Factor XI. The results demonstrated strong antithrombotic effects with no clinically relevant bleeding, offering promising anticoagulant options for patients at varying bleeding risks.
During the fiscal third quarter that ended September 30, 2024, REGN's revenues increased 10.6% year-over-year to $ 3.72 billion. Its income from operations grew 6.1% from the year-ago value to $ 1.18 billion. In addition, the company's non-GAAP net income and non-GAAP net income per share came in at $ 1.46 billion and $12.46, up 10% and 7.5% over the prior-year quarter, respectively.
Street expects REGN's revenue and EPS for the year ending December 31, 2024, to increase 8.1% and 2.9% year-over-year to $ 14.18 billion and $45.07, respectively. In addition, it surpassed the consensus revenue and EPS estimates in three of the trailing four quarters.
Shares of REGN have gained marginally year-to-date to close the last trading session at $716.26.
REGN's POWR Ratings reflect its robust outlook. The stock has an overall rating of B, equating to a Buy in our proprietary rating system.
It has a B grade in Value, Sentiment, and Quality. It is ranked #21 in the same industry.
Click <a href="https://stocknews.com/stock/REGN/">here</a> to see REGN's ratings for Growth, Momentum, and Stability.
Stock #1: Gilead Sciences, Inc. (<a href="https://stocknews.com/stock/GILD/">GILD</a>)
GILD is a biopharmaceutical company specializing in treatments for HIV/AIDS, COVID-19, viral hepatitis, oncology, and pulmonary hypertension. Its key products include Biktarvy, Veklury, and Yescarta, and it collaborates with several partners to advance research and innovative therapies.
On December 17, GILD and Terray Therapeutics, Inc. announced a strategic collaboration aimed at discovering and developing innovative small molecule therapies targeting multiple disease areas. This partnership underscores Gilead's commitment to expanding its therapeutic portfolio through cutting-edge scientific alliances.
On November 14, GILD announced the pricing of $3.5 billion in senior unsecured notes, with varying maturities from 2029 to 2064. The offering is expected to close on November 20, 2024, and will support the company's financial strategies and growth initiatives.
It pays an annual dividend of $3.08, which translates to a dividend yield of 3.33% at the prevailing price levels. Its four-year average dividend yield is 4.05%. The company has grown its dividend payment at a CAGR of 4.1% over the past five years.
GILD's total revenues increased 7% year-over-year to $7.55 billion in the fiscal third quarter that ended on September 30, 2024. Its non-GAAP operating income came in at $3.26 billion, up 1.1% year-over-year. Moreover, its non-GAAP net income attributable to Gilead and non-GAAP earnings per share attributable to Gilead stood at $2.53 billion and $2.02, respectively, over the previous quarter.
Street expects GILD's revenue for the fiscal fourth quarter (ending December 31, 2024) to increase marginally year-over-year to $7.16 billion. Its EPS for the same quarter is likely to be $1.72. In addition, it surpassed the consensus revenue estimates in each of the trailing four quarters.
Shares of GILD have gained 8.6% over the past year and 35.1% over the past six months to close the last trading session at $91.23.
GILD's bright prospects are apparent in its POWR Ratings. The stock has an overall rating of A, which translates to a Strong Buy in our proprietary rating system.
It has an A grade for Sentiment and a B for Value, Growth, and Quality. It tops the same industry.
Click <a href="https://stocknews.com/stock/GILD/">here</a> to see GILD's ratings for Momentum and Stability.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
GILD shares fell $0.41 (-0.45%) in premarket trading Tuesday. Year-to-date, GILD has declined -1.23%, versus a 1.58% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Kritika Sarmah</h2> <img src='https:/wp-content/uploads/2022/08/Kritika-Sarmah_Image-3.jpg' style="float:left; padding:5px;width:125px;">Her interest in risky instruments and passion for writing made Kritika an analyst and financial journalist. She earned her bachelor's degree in commerce and is currently pursuing the CFA program. With her fundamental approach, she aims to help investors identify untapped investment opportunities.<a href="https://stocknews.com/authors/?author=kritika-sarmah">More...</a>The post <a href=https://stocknews.com/news/gild-vrtx-regn-3-biotech-innovators-advancing-genetic-therapies/>3 Biotech Innovators Advancing Genetic Therapies</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Biotech Innovators Advancing Genetic Therapies

ADBE

ALHC

AMZN

APPF

ATRO

AVAV

AVPT

AXON

BEAM

BWIN

CAVA

CBLL

CDNA

CRSP

DXCM

EDIT

GDYN

GILD

GWRE

INOD

KIDS

KRUS

LNTH

MPTI

MPWR

MRNA

MYRG

NSSC

NTLA

ODFL

PCTY

PEGA

PNFP

PYCR

REGN

RXST

SAIA

SARO

SIBN

SPSC

TNDM

TOST

TSLA

USAP

VERX

VRRM

WDAY

WEAV

WING

XMTR

Screenshot 2024-09-30 at 9.13.36 PM

TNXP

The Rush For Non-Addictive Painkillers To Counter The Opioid Crisis Puts Two Companies Closer To FDA Decisions

Press Releases

Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the American Society of Hematology (ASH) Annual Meeting and Exposition and Provides Program Update

Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy

Vertex Pharmaceuticals Inc. (VRTX) Investigated For Securities Fraud; Block & Leviton Encourages Investors Who Have Lost Money to Contact the Firm

Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non-F508del TRIKAFTA-Responsive Variants

Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis

Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13

Orna Therapeutics Establishes Strategic Collaboration with Vertex Pharmaceuticals to Develop Next Generation Approaches for Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)

Zai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore

Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore

Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings

Comments

Vertex Pharmaceuticals

ニュース

最新ニュース Vertex Pharmaceuticals (NASDAQ:VRTX) 株価情報

水曜日, 7 31, 2024

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル